Diese Webseite verwendet Cookies

Diese Seite verwendet Cookies, um Ihnen dieses Angebot leicht zugänglich zu machen, Inhalte zu personalisieren, Ihre Zugriffe auf die Webseite zu analysieren und Ihnen ggf. personalisierte Angebote unterbreiten zu können. Hierzu kann es notwendig sein, dass die Informationen über Ihre Verwendung der Webseite an Partner weitergegeben werden. Diese führen die gesammelten Informationen möglicherweise mit weiteren Daten zusammen, die Sie an anderer Stelle bereitgestellt haben. Eine Weitergabe erfolgt dabei aber nur mit Ihrer Einwilligung und unter Beachtung der datenschutzrechtlichen Vorgaben. Weiterführende Informationen über die hier verwendeten Cookies erfahren Sie in den folgenden Erklärungen zu den jeweiligen Cookies.

Notwendige Cookies helfen dabei, Ihnen die Funktionen der Webseite zugängig zu machen, indem sie Grundfunktionen die zuletzt angesehen Wertpapiere und Ihre Entscheidung für oder gegen die Nutzung der jeweiligen Cookies speichert. Die Webseite wird ohne diese Cookies nicht so funktionieren, wie es geplant ist.

Name Anbieter Zweck Ablauf Typ Verantwortlicher
CookieConsent324 Moneyspecial Um diese Cookiebar auszublenden. 1 Jahr http Infront Financial Technology GmbH
Die Cookie-Erklärung wurde das letzte Mal am 17.07.2020 von Infront Financial Technology GmbH aktualisiert.
Drucken

12.01.2022 - 14:30

GlobeNewswire: Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring Americans to understand their relationship with sleep

Jennifer Aniston partners with Idorsia U.S. to launch 'Seize the Night & Day'
campaign inspiring Americans to understand their relationship with sleep

Jennifer Aniston partners with Idorsia U.S. to launch 'Seize the Night & Day'
campaign inspiring Americans to understand their relationship with sleep
Jennifer reveals for the first time her sleep story spanning many years of
challenges and how she has learned to make sleep a priority to have both better
nights and days National education campaign provides a beacon of hope by
shining a light on the approximately 25 million adults in the US living with
insomnia Campaign provides educational resources to help people and healthcare
providers understand insomnia's dual impact that affects both nights and days

Allschwil, Switzerland & Radnor, PA, US - January 12 , 2022
Idorsia Ltd (SIX: IDIA) and Idorsia Pharmaceuticals, US Inc. today announced
its partnership with award-winning actor and director/producer Jennifer Aniston
to launch Seize the Night & Day , an integrated educational campaign aimed at
revealing insomnia's dual impact that affects both nights and days. The
national initiative sheds light on the reality of insomnia for the millions of
Americans living with this very real, but often overlooked medical condition.
Idorsia and Jen have forged a multi-year collaboration with the shared goal of
informing, inspiring and empowering people to take the first steps towards
quality sleep through education, actionable information and community support.

Jen, for the first time, is sharing her very personal sleep story and the
impact that sleep issues have had on both her nights and days. Her goal is to
help those who aren't getting the quality sleep they deserve better understand
that they're not alone when it comes to trouble sleeping.

Sleep, nutrition and physical activity comprise the three pillars of health.
Sleep is often overshadowed by diet and exercise, however its impact on people
is becoming better understood. Insomnia is the most prevalent sleep disorder in
the US, affecting approximately 25 million adults. 1 Lack of quality sleep can
impair people's daily lives, including the ability to concentrate, mood and
energy levels. 2 In the long-term, insomnia is associated with an increased
risk of numerous serious health conditions, such as psychiatric disorders,
cardiovascular disease, type 2 diabetes, substance abuse and dementia. 3, 4, 5


Jennifer Aniston commented:
"My challenges with sleep began many years ago - so it's such a priority for
my overall health. If I don't get a good night's sleep, my next day is really
difficult. In working with Idorsia, I hope that we can all start prioritizing
sleep health and have different conversations around trouble sleeping."

Visit ' Seize the Night & Day ' to hear more about Jen's sleep story.

As part of the campaign, Jen will be featured in digital and television
advertising that brings to life how people are not themselves when they don't
get quality sleep. Additionally, the campaign has online educational resources
that explore the science behind insomnia and its dual impact that affects both
nights and days; tips to get a better night's rest and creating a sleep
routine; and a community forum where people can connect with others to share
positive sleep affirmations.

Patricia Torr, President and General Manager of Idorsia US commented:
"Seize the Night & Day exemplifies Idorsia's commitment to providing people
living with insomnia the information they need to take the first step in
improving their sleep. Jen is a natural partner for the campaign as she has had
trouble sleeping for many years. We share a unified vision of helping others
understand how insomnia's dual impact affects both nights and days and the
importance of quality sleep."

To learn more about # SeizetheNightandDay visit the consumer and HCP websites
and follow the conversation on Twitter , Facebook , Instagram and LinkedIn .

Notes to the editor

About Jen Aniston's Sleep Story
Jen Aniston has had trouble sleeping for nearly 20 years and knows first-hand
how important it is to make sleep health a priority. Over the years, she's
learned the importance of quality sleep and creating good sleep habits. Jen
wants to inspire others who have trouble sleeping to prioritize their sleep
health and encourage them to get educated on how trouble sleeping can impact
not only their nights, but their days too. Most importantly, she wants people
to remember that they are not alone. Through Seize the Night & Day, Jen is able
to help provide people with trouble sleeping the necessary educational
resources and tools to ensure they too have rested nights and refreshed days.

About Insomnia
Insomnia is defined as a combination of difficulty obtaining sufficient sleep
and dissatisfaction with sleep combined with a significant negative impact on
daytime functioning. Insomnia disorder is defined as difficulty initiating
and/or maintaining sleep on at least three nights per week for at least three
months, despite adequate opportunity to sleep.

Insomnia is a condition of overactive brain activity during sleep, and studies
have shown that areas of the brain associated with wakefulness remain more
active during sleep in patients with insomnia.

Significant insomnia is a common problem with a prevalence of approximately
10%. On this basis, and assuming a US adult population of around 250 million,
there are approximately 25 million adults in the US living with insomnia.

Insomnia as a chronic disorder is different from a brief period of poor sleep,
and it can take its toll on both physical and mental health. It can be a
persistent condition with a negative impact on daytime functioning. Idorsia's
research has shown that poor-quality sleep can affect many aspects of daily
life, including the ability to concentrate, mood, and energy levels.

The goals of managing insomnia are to improve sleep quality and quantity, as
well as daytime functioning. Current recommended treatment of insomnia includes
sleep hygiene recommendations, cognitive behavioral therapy, and
pharmacotherapy.

References Bhaskar S, Hemavathy D, Prasad S. Prevalence of chronic insomnia in
adult patients and its correlation with medical comorbidities. J Family Med
Prim Care. 2016;5(4):780-784. doi:10.4103/2249-4863.201153. Ustinov Y,
Lichstein KL, Wal GS, Taylor DJ, Riedel BW, Bush AJ. Association between report
of insomnia and daytime functioning. Sleep Med. 2010 Jan;11(1):65-8.
doi:10.1016/j.sleep.2009.07.009. Epub 2009 Sep 23. Olfson M, Wall M, Liu SM,
Morin CM, Blanco C. Insomnia and Impaired Quality of Life in the United States.
J Clin Psychiatry. 2018 Sep 11;79(5):17m12020. doi: 10.4088/JCP.17m12020.
Doghramji K. The epidemiology and diagnosis of insomnia. Am J Manag Care. 2006
May;12(8 Suppl): S214-20. PMID: 16686591. de Almondes KM, Costa MV,
Malloy-Diniz LF, Diniz BS. Insomnia and risk of dementia in older adults:
Systematic review and meta-analysis. J Psychiatr Res. 2016 Jun;77:109-15. doi:
10.1016/j.jpsychires.2016.02.021. Epub 2016 Mar 8. PMID: 27017287.



About Idorsia US
Idorsia US, an affiliate of Idorsia, is reaching out for more - we have more
ideas, we see more opportunities, and we want to help more patients. To achieve
this, we will help develop Idorsia into a leading biopharmaceutical company,
with a strong scientific core. With commercial operations based outside of
Philadelphia, PA, one of densest communities of life sciences talent in the
world, we are helping to realize the company's ambition of bringing innovative
medicines from bench to bedside. Our goal is to build a commercial footprint
that will deliver Idorsia's deep pipeline of products from its R&D engine to
the US market - with the potential to change the lives of many patients.

About Idorsia
Idorsia Ltd is reaching out for more - We have more ideas, we see more
opportunities and we want to help more patients. In order to achieve this, we
will develop Idorsia into a leading biopharmaceutical company, with a strong
scientific core.

Headquartered near Basel, Switzerland - a European biotech-hub - Idorsia is
specialized in the discovery, development and commercialization of small
molecules to transform the horizon of therapeutic options. Idorsia has a broad
portfolio of innovative drugs in the pipeline, an experienced team of
professionals covering all disciplines from bench to bedside, state-of-the-art
facilities, and a strong balance sheet - the ideal constellation to translate
R&D efforts into business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June
2017 and has over 1'000 highly qualified specialists dedicated to realizing our
ambitious targets.

For further information, please contact

US Media
Christopher Clark
Senior Director, US Head of Communications
Idorsia Pharmaceuticals US, 100 Matsonford Road, Radnor, PA 19087
+1 (215) 421 4887
christopher.clark@idorsia.com
www.idorsia.us

Global Investors & Media
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com

The above information contains certain "forward-looking statements", relating
to the company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects", "may",
"are expected to", "will", "will continue", "should", "would be", "seeks",
"pending" or "anticipates" or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions of the
company's investment and research and development programs and anticipated
expenditures in connection therewith, descriptions of new products expected to
be introduced by the company and anticipated customer demand for such products
and products in the company's existing portfolio. Such statements reflect the
current views of the company with respect to future events and are subject to
certain risks, uncertainties and assumptions. Many factors could cause the
actual results, performance or achievements of the company to be materially
different from any future results, performances or achievements that may be
expressed or implied by such forward-looking statements. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those described herein
as anticipated, believed, estimated or expected.



Anhang Medienmitteilung PDF

Mehr Marktdaten und Kurse finden Sie auf www.finanztreff.de

Angebote der
Nutzungshinweise | Datenschutz | Impressum | Datenquellen: boerse-stuttgart.de,